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We identify an NLS within herpes simplex virus scaffold proteins that is required for optimal nuclear
import of these proteins into infected or uninfected nuclei, and is sufﬁcient to mediate nuclear import
of GFP. A virus lacking this NLS replicated to titers reduced by 1000-fold, but was able to make capsids
containing both scaffold and portal proteins suggesting that other functions can complement the NLS
in infected cells. We also show that Vp22a, the major scaffold protein, is sufﬁcient to mediate the
incorporation of portal protein into capsids, whereas proper portal immunoreactivity in the capsid
requires the larger scaffold protein pUL26. Finally, capsid angularization in infected cells did not require
the HSV-1 protease unless full length pUL26 was expressed. These data suggest that the HSV-1 portal
undergoes conformational changes during capsid maturation, and reveal that full length pUL26 is
required for this conformational change.
& 2012 Elsevier Inc. All rights reserved.Introduction
Herpes simplex virus (HSV) procapsids comprise an internal
scaffold, which in productive cases is replaced with DNA, and an
external shell that is maintained in the infectious virion [reviewed
in (Baines and Duffy, 2006;Conway and Homa, 2011)]. A unique
vertex, termed the portal vertex, is incorporated into each capsid
and comprises a dodecamer of the UL6 gene product (Newcomb
et al., 2001). The portal vertex is so named because it forms the
pore through which DNA is inserted and eventually expelled
during initiation of viral infection. It is believed that to ensure
that only one portal vertex is incorporated into each capsid,
assembly is initiated by an interaction between the portal protein
(product of the UL6 open reading frame, or pUL6) and scaffold
proteins (Newcomb et al., 2005). This interaction involves amino
acids 143–151 of VP22a, an abundant scaffold component
(Huffman et al., 2008;Yang and Baines, 2008). Subsequent inter-
actions between portal-bound scaffold proteins and capsomeres
consisting of scaffold proteins bound to VP5, the major compo-
nent of the outer shell, eventually produce the roughly spherical
procapsid (Trus et al., 1996; Newcomb et al., 2003; Preston and
McDougall, 2002; Warner et al., 2000; Warner et al., 2001). The
external shell is further fortiﬁed by interactions with triplexes,
consisting of the products of the UL18 and UL38 genes whichll rights reserved.
York State College of
4853, USA.are designated VP23 and VP19c, respectively (Newcomb et al.,
1993;Gibson and Roizman, 1972). On or about the time of DNA
packaging and scaffold removal, the outer shell undergoes a
dramatic conformational change to become less porous and more
stable, essentially locking the DNA within the capsid (Newcomb
et al., 1996; Trus et al., 1996).
The scaffold within a single capsid comprises approximately
1100 copies of the UL26.5 protein (termed VP22a or ICP35)
and 87–147 copies of the UL26 gene product (termed pUL26)
(Newcomb et al., 1993; Steven and Spear, 1997). UL26.5 lies co-
terminal with UL26, causing the two encoded proteins to share
signiﬁcant amino acid identity (see Fig. 1) (Liu and Roizman,
1991). The N-terminus of UL26, however, is unique and encodes a
protease that cleaves pUL26 at two sites: between amino acid
(AA) 247 and 248, and between AA 610 and 611 (Deckman et al.,
1992; DiIanni et al., 1993). The proteolytic cleavage at AA 247
releases VP24 from the N-terminus and VP21 from the C-termi-
nus (Davison et al., 1992). The protease also cleaves VP22a at the
corresponding C-terminal site (i.e. between Vp22a AAs 303 and
304) (Preston et al., 1992; DiIanni et al., 1993).
The C-terminal cleavage events (termed maturation or M site
cleavage events) likely contribute to capsid maturation because
regions of VP22a and VP21 C terminal to the M site bind the
N-terminus of VP5 in the outer shell (Desai and Person, 1999; Hong
et al., 1996;Warner et al., 2001). The cleavage therefore releases
the linkage between the inner and outer protein layers, presum-
ably facilitating removal of the internal scaffold and promoting
conformational changes in the outer shell. The purpose of the
cleavage event at pUL26 AA 247 (termed the release or R cleavage
Fig. 1. Schematic representation of UL26 or UL26.5 open frame of expression
plasmids, cell lines and recombinant viruses. All the constructs were made as
described in materials and methods, and the designation of the constructs and
genotype are indicated on the right. Numbers in parentheses refer to pUL26 or
pUL26.5 codons/amino acids, either the total number of codons in the open
reading frame or the speciﬁc mutation in that construct. The vertical arrow at Met
307 initiates the UL26.5 open reading frame. A star indicates the location of an H to
A point mutation in the protease domain previously shown to preclude protease
activity (Register and Shafer, 1997). An ‘‘X’’ indicates the point of insertion of a
stop codon at codon 44. Del, deletion.
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DNA packaging (Matusick-Kumar et al., 1995). R cleavage frees the
protease (VP24) from the rest of pUL26, potentially allowing its
diffusion within the capsid to enhance cleavage of multiple VP5/
scaffold linkages, or to efﬁciently remove constraints on capsid
rearrangement that full length pUL26 might impose. The effect of
protease release on the portal is not known.
Because an incorrectly assembled capsomere might preclude
successful assembly of the entire capsid, HSV utilizes a number of
quality control mechanisms during assembly. For example, VP5
lacks a nuclear localization signal (NLS), so does not enter the
nucleus unless coexpressed with either the scaffold protein VP22a
or triplex protein VP19C (Nicholson et al., 1994; Rixon et al.,
1996). Thus, free VP5 is not available to the growing capsid
sphere. Such an event might be detrimental because a single VP5
molecule lacking a bound scaffold protein, would potentially
compromise formation of the scaffold. With the hypothesis that
similar mechanisms might regulate protease incorporation into
the nucleus, preliminary in silico analysis noted a potential NLS
within pUL26 (amino acids 426–429) using the predictor program
PSORTII (data not shown). This sequence was identiﬁed pre-
viously as NLS-1, one of two potential NLSes in human cytome-
galovirus (HCMV) scaffold proteins and, unlike NLS-2, was shown
to be conserved in the scaffolding proteins of many different
herpesviruses (Plafker and Gibson, 1998). Although previously
shown to be important for nuclear import HCMV scaffold proteins
(Plafker and Gibson, 1998), NLS-1 was largely dispensable for
viral replication, reducing viral titers by approximately 3-fold
when mutated (Nguyen et al., 2008). In contrast, mutation of NLS-2 reduced HCMV titers by approximately 140-fold. Whether the
counterpart sequence of NLS-1 actually comprised an NLS in HSV
was unknown. The role of this sequence in nuclear import of
pUL26 during transient expression and in infected cells is inves-
tigated in the current study.
We also generated mutant viruses in which either the protease
was rendered nonfunctional through a single point mutation at its
active site, or the gene encoding it was truncated by insertion of
a stop codon. Analyses indicated that the stop codon mutant
rendered the portal protein less accessible to portal-speciﬁc
antibodies suggesting that the portal, like the rest of the capsid
shell, undergoes a conformational change during capsid matura-
tion. Consistent with previous studies, the mutation blocking
protease activity impaired angularization of capsids as revealed
by electron microscopy (Register and Shafer, 1997; Gao et al.,
1994). These data help explain the essential roles of the HSV-1
protease in capsid maturation and DNA packaging.Results
Previous studies (Plafker and Gibson, 1998) and preliminary in
silico analysis noted a basic region within a potential NLS (pattern 4)
within pUL26 using the predictor program PSORTII. The basic core
of this putative NLS included pUL26 amino acids 426–429 or KRRR.
To test the relevance of this sequence to nuclear import of pUL26,
CV1 cells were transfected with plasmids encoding FLAG-tagged
full length UL26 (designated pJB466) or a UL26 mutant plasmid
(designated pJB583) that lacked codons 426–429. Cells transfected
with the plasmids were ﬁxed 24 h after transfection, permeabilized
and immunostained with antibody recognizing the FLAG epitope or
an antibody recognizing the C-terminus of pUL26, which is also
present within the scaffold protein VP22a. Bound antibody was
revealed by reaction with goat anti-mouse immunoglobulins con-
jugated to Alexa Fluor 568 (red) and the stained cells were viewed
on a conventional ﬂuorescence microscope. The results are shown
in Fig. 2.
As revealed by anti-FLAG immunostaining, deletion of codons
426–429 caused pUL26 to localize exclusively in the cytoplasm
whereas wild type Flag-UL26 localized primarily in the nucleus.
Similarly, while immunostaining in cells expressing wild type
pUL26 with anti-VP22a/pUL26 antibody localized in the nucleus in
cells expressing wild type pUL26, whereas deletion of UL26 codons
426–429 caused VP22a/pUL26-speciﬁc immunostaining to appear
in the cytoplasm.
To test the effect of the NLS on nuclear export of VP22a, an
expression plasmid bearing UL26.5 lacking or containing the
equivalent codons 426–429 of pUL26 was transfected, and the
cells were ﬁxed and immunostained with the anti-VP22a/pUL26
antibody as detailed above. The results, shown in Fig. 2B, indi-
cated that VP22a lacking the putative NLS localized predomi-
nantly within the nucleus, although some signal was also
detected in the cytoplasm of some cells. Wild type VP22a
accumulated exclusively in the nucleus. Thus, although the NLS
in VP22a augmented nuclear localization, it was ultimately
dispensable for this localization. We speculate that this result
reﬂects the small size of VP22a which allows its diffusion through
the nuclear pore in the absence of an NLS. A similar result was
obtained in the analysis of the counterpart CMV protein lacking
NLS-1 (Plafker and Gibson, 1998). We conclude that codons 426–
429 are required for pUL26 to enter the nucleus when expressed
in the absence of other viral proteins.
To determine whether the putative NLS was sufﬁcient to
localize a protein into the nucleus, a plasmid encoding EGFP
fused to amino acids DPGVRGSGKRRRY, was constructed and
transfected into CV1 cells. As a control, plasmids encoding EGFP
Fig. 2. Localization of pUL26 or in uninfected cells. (Panel A) Plasmids encoding the indicated proteins were transfected into CV1 cells, and the distribution of pUL26 or
VP22a was examined by indirect immunoﬂuorescence using anti-Flag (M2 antibody) or anti-VP22a (antibody designated MCA406) mouse monoclonal antibodies, followed
by reacting with Alexa Fluor 568-labeled goat anti-mouse IgG (red). The nuclei of transfected cells were stained with Hoechst stain. Digital images from a Zeiss Axio Imager
M1 microscope were compiled with Photoshop SC3 software. (Panel B) Localization of transiently expressed VP22a (encoded by UL26.5) containing or lacking a putative
NLS. Plasmids as diagramed in Fig. 1 (pJB139, upper panel; pJB582, lower panel) and encoding the indicated proteins were transfected into CV1 cells. The cells were ﬁxed
24 h later, stained with Hoechst stain, and immunostained with anti-VP22a antibody. The cells were visualized as described for panel A. A thick arrow indicates a cell with
both cytoplasmic and nuclear ﬂuorescence. A thin arrow indicates a cell with solely nuclear ﬂuorescence. (Panel C) EGFP or pUL26 NLS-EGFP intracellular distribution in
transfected cells. Cells were transfected with EGFP or EGFP fused to pUL26 amino acids 426-KRRRY-430 or pUL26 amino acids 418-DPGVRGSGKRRRY-430. Transfected cells
were ﬁxed 24 h later, counterstained with Hoescht stain, and visualized in a Zeiss ﬂuorescence microscope. Digital images were compiled with Adobe Photoshop.
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CV1 cells in parallel. Visualizing the cells by conventional micro-
scopy (Fig. 2B) revealed that EGFP alone, or EGFP fused to amino
acids KRRRY localized in the nucleus and cytoplasm, whereas the
UL26 sequences DPGVRGSGKRRY conferred exclusive nuclear loca-
lization to EGFP. We conclude that amino acids DPGVRGSGKRRY of
UL26 can serve as an NLS when placed in the context of another
protein.
To examine the role of UL26 codons 426–429 on localization of
scaffold proteins in HSV infected cells, these codons were deleted
from an otherwise wild type HSV genome using recombinant BAC
technology. The resulting virus was designated vJB70 and a
schematic diagram of relevant sequences is shown in Fig. 1. Cells
were infected with the resulting virus and were immunostained
with antibodies directed against VP22a/pUL26 or pUL6 18 h later.
As a control, cells infected with HSV-1(F) were ﬁxed and immu-
nostained in parallel. As shown in Fig. 3, and similar to
the results obtained from sole expression of VP26 lacking its
NLS, VP22a/pUL26 speciﬁc staining accumulated to a substantial
extent in the cytoplasm of vJB70-infected cells. On the other hand,
substantial amounts of VP22a/pUL26 immunostaining lacking the
NLS localized to infected cell nuclei and colocalized with immu-
nostaining attributable to pUL6 (Fig. 3). This colocalization was
especially striking within intranuclear aggregates that localized at
the nuclear periphery. We conclude that while the NLS in pUL26/
VP22a facilitates intranuclear localization, it is not fully required.
We speculate that the intranuclear ﬂuorescence may in part be
attributable to VP22a which can diffuse into the nucleus without
an NLS (see Fig. 2B).
Given that some nuclear import of scaffold proteins occurred
in vJB70 infected cells, we next asked whether the mutation
altered viral replication. Preliminary results suggested that the
mutation greatly reduced viral replication inasmuch as rescue of
VJB70 on cell lines containing UL26 was very inefﬁcient, with peak
titers of viral stocks reduced at least 100-fold relative to wild type
virus (not shown). To more quantitatively test vJB70 replication,
CV1 cells, or CV1 cells expressing either wild type UL26(designated CV26), or UL26 lacking UL26 codons 426–429 (desig-
nated CV26M2) were infected with JB70, and the amount of
infectivity produced was measured on complementing CV26 cells.
As shown in Table 1, infectivity was reduced at least 100-fold
relative to wild type HSV-1(F) in all cell lines. The mutation was
not lethal inasmuch as residual viral replication was detected
under various conditions, including within (i) CV1 cells not
expressing viral proteins, and (ii) cells expressing the correspond-
ing mutant pUL26 that lacked the putative NLS. HSV-1(F) grew
normally in this cell line (designated CV26M2), indicating that the
mutant UL26 did not act in a dominant negative fashion.
Because AA 426-KRRR-429 greatly augmented viral replica-
tion, a series of experiments were then conducted to characterize
the replication defect of vJB70 lacking these sequences. Because
scaffold proteins are known to interact with the UL6 encoded
portal protein we asked whether the mutation in vJB70 interfered
with this interaction. CV1 cells were infected for 18 h with 5 PFU
per cell of wild type virus HSV-1(F), a UL6 null virus, vJB70, or a
novel virus, designated pJB71, containing a stop codon in place of
codon 44 of UL26 (i.e. lacking most of UL26 including the protease
encoded at the N-terminus; this virus was expected to encode
VP22a which is the product of the UL26.5 open reading frame).
Clariﬁed cellular lysates of cells infected with wild type and
mutant viruses were subjected to immunoprecipitation with
anti-VP22a mouse monoclonal antibody (MCA406). The immu-
noprecipitated proteins were electrophoretically separated on an
SDS-polyacrylamide gel, transferred to a nitrocellulose sheet and
subjected to immunoblotting with anti-pUL6, or anti-VP22a
antibodies.
As shown in Fig. 4, the anti-scaffold antibody immunoprecipi-
tated VP22a from all infected cell lysates. This antibody also
immunoprecipitated both pUL26, and VP21 (derived from proteo-
lytic cleavage of pUL26 and comprising its C-terminus), and
coimmunoprecipitated pUL6 from HSV-1(F) infected cell lysates.
Importantly, pUL6 was co-immunoprecipitated with anti-scaffold
antibody from lysates of cells infected with vJB71. pUL26 was not
immunoprecipitated from these lysates because the inserted stop
Fig. 3. Localization of VP22a and pUL6 in cells infected with a recombinant virus encoding wild type and mutant UL26. CV1 cells were infected for 18 h with the indicated
recombinant viruses at which time they were ﬁxed, permeabilized, and incubated with mouse anti-VP22a (MCA406) and rabbit anti-pUL6 antibodies. Bound antibodies
were revealed by reaction with Alexa Fluor 568-labeled goat anti-mouse IgG (red) and Alexa Fluor 488-labled goat anti-rabbit IgG (green). Nuclei were identiﬁed by
Hoechst counterstaining. All the images were collected with a Zeiss Axio Imager M1 microscope using a 63 oil immersion objective lens, and the images were taken with
an Axio CAM MRm camera (Zeiss). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 1
Replication of UL26 mutant viruses.
a
Virus CV1c CV26c CV26.5c CV26M1c (Lacks portal
interaction; D449–457aa)
CV26M2c
(Lacks NLS; D426–429aa)
HSV-1(F)b (1.771.1)106 (2.2570.35)106 (1.7470.35)106 (970.14)105 (270.7)106
vJB11b (D449–457aa)b o101 (270.87)104 (1.770.42)104 o101 (5.372.5)103
vJB70 (D426–429aa)b (4.870.76)102 (3.172.6)103 (1.2570.35)103 (371.4)102 (672.6)102
vJB71 (stop at 44aa)b o101 (3.7570.35)105 o101 (1.970.65)105 (2.871.4)103
vJB84 (H61A)b o101 (3.1271.04)105 ND (2.370.76) 105 (1.970.66)104
vJB70Rb 2106 1.0106 1.5106 1.2106 2.5106
vJB71Rb 1.2106 1.4106 1.5106 2106 1.0106
vJB84Rb 2106 1.6106 ND 2.6106 1.5106
a The assay was performed as described in Materials and methods, and the data are represented as mean7standard derivation from three independent experiments,
except for the genetically repaired viruses which were assayed once (bottom 3 rows).
b Viruses used in replication assays. HSV-1(F) is the wild type strain, whereas the others are recombinant viruses with mutations in UL26 (diagramed in Fig. 1) or a
virus (designated R) in which the corresponding mutation was repaired.
c The indicated cell lines were used to propagate HSV-1(F) or UL26 mutant viruses. Virus yields were determined by plaque assay on CV1 cells for HSV-1(F), or CV26
cells for UL26 mutant viruses.
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indicate that VP22a was sufﬁcient to mediate the interaction
with portal protein, even in the absence of full length pUL26.
In addition, VP22a, pUL26 and pUL6 were coimmunoprecipitated
with anti-scaffold antibody from lysates of cells infected with
vJB70, indicating that removal of amino acids 426–429 from
pUL26 did not interfere with the interactions between scaffold
proteins and the portal protein. Although we cannot formally
exclude the possibility that the interaction between portal and
scaffold was mediated indirectly inasmuch as both proteinsinteract with VP5, we note that the previously identiﬁed portal
interaction domain in scaffold proteins remained wild type in
vJB70 (Singer et al., 2005; Yang and Baines, 2008). Thus, we favor
the interpretation that scaffold/portal interactions were not dis-
rupted in vJB70 infected cells.
To further investigate this possibility, we determined whether
the mutation in vJB70 affected incorporation of portal protein into
capsids. Capsids were puriﬁed from cells infected with vJB70,
denatured, electrophoretically separated, transferred to nitrocel-
lulose and probed with pUL6-speciﬁc antibody. As additional
Fig. 4. Interaction between pUL26 and pUL6 (portal) occurs in mutant virus-
infected cells. CV1 cells were infected for 18 h with 5 PFU per cell of the indicated
viruses and cells were washed with cold PBS, and lysed in RIPA buffer. Samples of
clariﬁed lysates (top two panels) were subjected to immunoblotting with
antibodies to pUL6 and pUL26. Soluble proteins in the lysates were subjected to
immunoprecipitation with anti-VP22a mouse monoclonal antibody (MCA406;
bottom two panels). Immunoprecipitated proteins were separated on an SDS-
polyacrylamide gel, transferred to nitrocellulose membranes, and detected by
immunoblotting with anti-pUL6, or anti-VP22a antibodies. Bound immunoglobu-
lins were revealed by enhanced chemiluminescence followed by exposure to X ray
ﬁlm. IP, immunoprecipitating antibody; IB antibody used for immunoblotting.
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virus HSV-1(F), a UL6 null virus, and vJB71. In vJB71 infected cells,
it was expected that pUL26 would not be made and only VP22a
would be detected. The results are shown in Fig. 5, panel A.
As expected, capsids from cells infected with the UL6 null virus
lacked UL6 immunoreactivity. In contrast, capsids from both
vJB70 and vJB71 infected cells contained readily detectable pUL6.
Although in this particular experiment the amount of portal protein
appeared greater in vJB71 capsids, normalizing to VP5-speciﬁc
bands in multiple experiments did not reveal consistent differences
in pUL6 amounts in the different capsids (data not shown). We
conclude that despite the lack of protease (vJB71) or NLS (vJB70)
within pUL26, capsids were assembled and portal protein was
incorporated into capsids.
Given that the portal protein was incorporated into capsids, we
next asked whether the portal protein was conformationally
correct. To examine portal conformation, capsids were puriﬁed
from cells infected with wild type HSV-1(F), vJB70, vJB71, and a UL6
null virus. The puriﬁed intact capsids were transferred to electron
microscopy grids and reacted with antibody against pUL6. Bound
antibody was revealed by reaction with gold-conjugated anti-rabbit
immunoglobulin followed by examination in an electron micro-
scope. Examples of the immunostained capsids from cells infected
with UL6 null virus, vJB71 and HSV-1(F) are shown in Fig. 5,
panels B, C and D, respectively. Fig. 5, panel E shows the average
percentage of capsids that were labeled with the UL6-speciﬁc
antibody (of approximately 900 of each capsid type examined).
Speciﬁcally, UL6-null capsids showed minimal labeling (less than
3%), whereas the anti-portal antibody labeled approximately 11% of
wild type HSV-1(F) capsids. Importantly for the purposes of this
experiment, vJB70 contained labeling that was reduced, butstatistically similar (p40.05) to that of wild type capsids, whereas
vJB71 contained signiﬁcantly less (po0.01) immunogold labeling.
We conclude that while the NLS within scaffold proteins is not
required for immunoreactivity of the portal on immunoblots, the
presence of the viral protease is required for immunoreactivity at
the capsid surface with portal speciﬁc antibody. This observation
suggests that pJB71 has an altered portal conformation. It follows
that inasmuch as the protease is missing from pJB71 capsids that
the viral protease is required for proper portal conformation.
In an attempt to conﬁrm that protease activity was required for
proper portal conformation, we constructed a new virus, desig-
nated vJB84 as shown in Fig. 1, that contained an alanine codon in
place of histidine 61, which comprises a site critical for protease
activity (Liu and Roizman, 1992; Register and Shafer, 1997).
Unfortunately for the purposes of this experiment, lysates did
not yield discernible light refracting bands on sucrose gradients
(data not shown). To determine the fate of vJB84 capsids in the
course of infection, cells infected with vJB84 were embedded,
sectioned and examined by electron microscopy. As shown in
Fig. 6, and in contrast to wild type capsids examined in parallel,
the morphology of the vJB84 capsids exclusively resembled those
of procapsids or large cored B capsids. Speciﬁcally, vJB84 capsids
were spherical and lacked electron dense cores. Most of these
particles were tightly clustered in the nucleoplasm. Similar obser-
vations have been reported in analyses of other protease mutants
(Register and Shafer, 1997;Gao et al., 1994;Preston et al., 1983).
Rarely, such particles were observed in the current study to
accumulate in the perinuclear space (indicated by arrows, Fig. 6)
with an additional structure surrounding the capsid, suggesting
that they had become enveloped (albeit inefﬁciently) at the inner
nuclear membrane. We conclude that blocking protease activity
precluded capsid maturation, and speculate that the inherent
instability of the procapsids noted in previous studies precluded
their separation on sucrose gradients (Newcomb et al., 2000).
As shown in Table 1, the replication of the viral mutants used
in these studies was determined in CV1 cell lines expressing or
not expressing wild type and mutant scaffold proteins. Schematic
diagrams of the viral sequences in the various cell lines are
indicated in Fig. 1. The results were as follows:(i) Expression of neither wild type nor mutant scaffold proteins
interfered with replication of wild type virus inasmuch as
titers of HSV-1(F) on all the cell lines were similar.(ii) vJB11, which lacks a domain necessary for interaction with
the portal protein was unable to replicate on CV1 and
CV26M1 cells (expressing UL26 but lacking the portal protein
interaction domain), indicating that the interaction with
portal was essential for viral replication. Replication of
vJB11 was rescued on cell lines expressing wild type scaffold
proteins (designated CV26 and CV26.5) that presumably
provided the portal interaction domain. Of interest was the
observation that vJB11 grew well on cells expressing only
UL26.5 (designated CV26.5). Thus, the smaller and more
abundant scaffold protein VP22a is sufﬁcient to incorporate
functional portal into capsids even in the absence of a portal
interaction domain within the larger scaffold protein pUL26.(iii) Neither the UL26 truncation mutant (vJB71) nor the virus
encoding an inactive protease (vJB84) replicated to appreciable
extents on CV1 cells or CV1 cells expressing only UL26.5. Thus,
as has been shown previously, protease activity and its release
from pUL26 are necessary for viral replication (Matusick-Kumar
et al., 1995). As expected, both the truncation mutant and
protease mutant grew well on cells expressing wild type pUL26.(iv) vJB71 was rescued efﬁciently on CV26M1 cells (expressing
UL26 but lacking the portal protein interaction domain)
suggesting that in this case the HSV protease encoded by the
Fig. 5. Analysis of portal in mutant virus capsids. (Panel A) Immunoblot of puriﬁed denatured B capsids probed with anti-PUL6 or VP5-speciﬁc antibodies. CV1 cells were
infected with 5 PFU of UL6 null, HSV-1(F) or UL26 mutant virus for 24 h, and the capsids were extracted, layered onto 20–50% sucrose gradients, and centrifuged at
24,500 rpm (SW41 rotor) for 1 h. B capsids were collected, denatured in SDS sample buffer, separated on an SDS-polyacrylamide gel and subjected to immunoblotting with
anti-pUL6 or anti-VP5 antibodies. (Panel B) UL6 null capsids were puriﬁed, attached to carbon coated grids, and reacted with anti-pUL6 rabbit antibody preadsorbed against
UL6 null capsids. Bound antibody was revealed by reaction with anti-rabbit IgG conjugated to 8–10 nm colloidal gold beads, followed by electron microscopic examination.
(Panel C) vJB71 B capsids were subjected to immunogold electron microscopy as described in the legend to panel B. (Panel D) Wild type capsids were subjected to
immunogold electron microscopy as described in the legend to panel B. (Panel E) A total of 900 capsids from the electron microscopic analysis as described in panels B, C
and D were counted and scored for the presence of gold beads. The results are shown as the average percentage of labeling from three independent experiments. GraphPad
software was used to apply statistical analyses of the data using Fisher’s exact test. vJB71 capsids, containing a truncated pUL26, contain statistically lower portal-speciﬁc
immunoreactivity than wild type capsids (Po0.01), whereas vJB70 lacking a putative NLS within scaffold proteins did not (pZ0.05).
K. Yang et al. / Virology 429 (2012) 63–73 69cell line was sufﬁcient to support viral replication, whereas
the scaffold interaction domain was supplied by the UL26.5
gene produced within the virus.(v) VJB84 replication was rescued in cells expressing mutant
pUL26 lacking either the NLS or portal interaction domain.
These data indicate that the UL26 mutations in the cell lines
did not interfere with protease activity or its release frompUL26. In these cases, portal interaction and the NLS were
likely supplied by pUL26 encoded by the virus.Discussion
The data in this report conﬁrms and expands on previous
observations that protease activity is necessary for capsid
Fig. 6. Analysis of capsid morphology in the absence of HSV-1 protease activity.
Capsids were puriﬁed from cells infected with wild type virus HSV-1(F) (upper
panel) or mutant virus vJB84 (lower panel) containing a point mutation that
precludes HSV protease activity. The cells were ﬁxed, embedded in Plastic, and
thin sections were examined by transmission electron microscopy. Nuc, nucleus;
cyto, cytoplasm; NM, nuclear membrane. Arrows in the lower panel indicate what
appear to be enveloped procapsids.
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Preston et al., 1983). Speciﬁcally, the current study shows that
protease activity is required for transition of the capsid from
largely spherical to angular, and to promote accessibility of
epitopes in the portal to portal-speciﬁc antibodies. These data
suggest that the portal undergoes some type of rearrangement
during capsid maturation. Such a maturational change in the
portal might be anticipated given its intimate association with the
outer shell, which is also rearranged dramatically during the
transition from procapsid to capsid (Heymann et al., 2003; Trus
et al., 1996; Cardone et al., 2007).
The exact portal rearrangement is vague given the genetic and
immunological approaches used in this study. A comparison
between the structure of the portal within the procapsid to that
in mature capsids may be particularly interesting to ascertain the
rearrangements involved. It is possible that the previous results
showing that R site cleavage is necessary for DNA packaging
reﬂect a role for this cleavage in making the portal competent for
DNA translocation, and for fostering dramatic capsid angulariza-
tion that occurs on or about the time of DNA packaging
(Matusick-Kumar et al., 1995;Trus et al., 1992). R site cleavagerenders the 635 AA pUL26 into considerably smaller fragments
(235 and 400 AA). Consistent with our observation that vJB84
infected cells contain only spherical capsids whereas truncation
of pUL26 allowed the formation of angular B capsids, it is likely
that the severing of the longest scaffold component (pUL26)
during R site cleavage is required to remove constraints that
otherwise impair rearrangement of the outer shell and portal. A
longstanding model is that R site cleavage may also promote
diffusion of the protease within the capsid, potentially allowing
more efﬁcient cleavage of other scaffold components to accelerate
outer capsid shell rearrangements (Matusick-Kumar et al., 1995;
Robertson et al., 1996).
We and others have shown previously that a peptide con-
tained within pUL26 and VP22a interacts with portal protein and
is necessary for its incorporation into capsids (Singer et al., 2005;
Yang and Baines, 2009). A virus (vJB11) lacking this scaffold
sequence replicated identically in cell lines expressing wild type
pUL26 or VP22a (Table 1). Thus, VP22a is sufﬁcient to provide
the required interaction with portal, even in the absence of the
identical sequence in pUL26.
These studies also identiﬁed an NLS within HSV scaffold
proteins. This sequence was necessary for nuclear import of
pUL26 during transient expression in uninfected cells, and was
sufﬁcient to mediate nuclear import of GFP. The absence of this
sequence reduced viral replication approximately 1000-fold, unlike
the case in HCMV where its mutation reduced infectious titers by
only 3-fold (Nguyen et al., 2008). This may be due, in part, to the
observation that unlike HSV, HCMV has an additional NLS (NLS-2)
which can mediate nuclear import of full length pNP1, the pUL26
ortholog, if NLS-1 is mutated. In transient expression assays Vp22a
lacking the NLS still entered the nucleus, presumably because,
unlike pUL26, it is small enough to enter the nuclear pore by
diffusion. In infected cells, the NLS in the smaller scaffold proteins
of HSV and HCMV help mediate nuclear import of the major capsid
protein (Nicholson et al., 1994; Rixon et al., 1996;Plafker and
Gibson, 1998). Other candidates to mediate nuclear import of
HSV scaffold proteins lacking the NLS in infected cells include the
portal protein, and triplex proteins that have been shown to
interact with VP5 and mediate its nuclear import (Nicholson
et al., 1994;Rixon et al., 1996; Yang et al., 2007).Material and methods
Cells, viruses, and antibodies
Procedures described previously were used to propagate CV1
and CV26 cells (Yang and Baines, 2009), and the viruses HSV-1
wild type strain F [HSV-1(F)], the UL6 null mutant derived from
HSV-1 strain 17 (Ejercito et al., 1968; Patel et al., 1996), or a
recombinant virus designated vJB11, which contains a deletion of
UL26 codons 449–457 (Yang and Baines, 2008). The mutation in
vJB11 precludes interaction between scaffold proteins and the
portal protein and incorporation of the portal protein into capsids
(Yang and Baines, 2008). Using procedures described previously,
monoclonal antibody MCA406 (Serotec, Inc.) was used to
detect VP21/VP22a, monoclonal antibody H1.4 (BIODESIGN, Cat#
C5014M) was used to detect VP5, and anti-pUL6 rabbit polyclonal
serum was used to detect the portal protein (Taus et al., 1998). For
immunogold microscopy of capsids, preabsorbed anti-pUL6 serum
was prepared as described previously (Yang et al., 2007).
Construction of recombinant viruses
The Bacterial Artiﬁcial Chromosome (BAC) containing the
entire HSV-1 (F) genome was used for constructing recombinant
K. Yang et al. / Virology 429 (2012) 63–73 71virus and was from Y. Kawaguchi (Tanaka et al., 2003). Plasmids
pEPkan-S containing aphAI [encoding kanamycin (kan) resistance]
and pBAD-I-SceI containing a gene encoding the I-SceI endonu-
clease were gifts from Nikolaus Osterrieder; plasmid pCAGGS-
nlsCre expressing Cre recombinase in mammanial cells was
obtained from Michael Kotlikoff, Cornell University.
Recombinant viruses constructed for this report include vJB70
which lack a putative NLS comprising pUL26 amino acids
426–429; vJB71, containing a stop codon at position 44 of UL26;
and vJB84, containing a histidine to alanine mutation at position
61 (H61A) that inactivates the proteolytic activities of pUL26
(Matusick-Kumar et al., 1995).
Recombinant viruses were constructed by the En Passant
method, a two-step bacteriophage l RED-mediated recombinant
system described by B.K. Tischer et al. and modiﬁed as described
(Tischer et al., 2006; Yang et al., 2007). The following primer pairs
with plasmid pEPkan-S as template were used to generate PCR
amplicons for homologous recombination.(i) To delete codons 426-KRRR-429 of pUL26: 50ccggccgcggg-
agaccctggggtccgggggtcgggatacgaggcggggccgtcgtagggataacag-
ggttaatcgattt30, (forward) and 50ctggtcgcagtaggactccgacggcc-
ccgcctcgtatcccgacccccggaccccgccagtgttacaaccaattaacc30,
(reverse).(ii) To insert a stop codon after position 44 of pUL26: 50gacag-
cggggactcgggcgagttggcattggatccggatacgTAGgtgcgggcggccct-
gcctccgtagggataacagggtaatcgattt30, (forward) and 50gttaatc-
gggagtgggttatccggaggcagggccgcccgcacCTAcgtatccggatccaatg-
ccaagccagtgttacaaccaattaacc30 (reverse) were used.(iii) To generate the point mutation H61A of pUL26, the primer
pairs were 50 gcg gcc ctg cct ccg gat aac cca ctc ccg att aac gtg
gac GCA cgcgctggctgcgaggtggggtag gga taa cag ggt aat cga
ttt30 (forward), and 50 gtc gac cac ggc cag cac ccg ccc cac ctc
gca gcc agc gcg TGC gtc cac gtt aat cgg gag tgggcc agt gtt aca
acc aat taa cc30 (reverse).The resulting recombinant BACs were designated bJB70, bJB71
and bJB84; the expected mutations in the respective UL26 genes
were conﬁrmed by DNA sequencing at the Cornell University DNA
Sequencing and Genotyping Core Facility. To reconstitute the
viruses, miniprep BAC DNA was puriﬁed and co-transfected with
a Cre expression plasmid using Superfect into CV1 cell lines
engineered to express full length pUL26 (designated CV26) (QIA-
GEN). The resulting viruses were subjected to two rounds of
plaque puriﬁcation on CV26 cells (see below). Diagrammatic
representation of the respective genotypes of the recombinant
viruses are shown in Fig. 1. To repair the mutation of the UL26
genes of recombinant viruses, CV1 cells were cotransfected with
the mutant viral genomes and a UL26-containing plasmid, fol-
lowed by plaque puriﬁcation on CV1 cells.
Construction of expression plasmids and cell lines
PCR amplicons containing the UL26 and UL26.5 genes dia-
gramed in Fig. 1 were cloned into pCDNA3 (for expression of
pUL26 transiently) or pCDNA5/FRT (for constructing recombinant
cell lines) at the HindIII and EcoRV sites. This places the genes
under the control of the major HCMV immediate early promoter/
enhancer. All the constructs were conﬁrmed by DNA sequencing.
Engineered cell lines were constructed using the Flp-IN-CV1
system (Invitrogen) according to the manufacture’s protocols and
as described previously (Liang et al., 2004). Flp-IN-CV1 cells were
purchased from Invitrogen and propagated in DMEM supplemen-
ted with 100 ug/ml of Zeocin. These cells served as progenitors of
all engineered cell lines in this report. The cell lines included
(i) CV26M1, expressing mutant pUL26 lacking the portalinteraction domain (i.e. UL26 codons 449–457), (ii) CV26.5, con-
taining the entire UL26.5 open reading frame driven by the early
CMV promoter/enhancer, and (iii) CV26M2, containing otherwise
full length UL26 but lacking a putative NLS comprising AA 426–
429 (see Fig. 1).
The resulting cell lines were maintained in DMEM supplemen-
ted with 10% calf serum, 200 ug/ml Hygromycin B, and the
expression of pUL26/pUL26.5 was conﬁrmed by immunoblotting
with anti-VP22a/pUL26 antibody (MCA406) (data not shown).
To fuse the putative nuclear localization signals of pUL26 to
enhanced green ﬂuorescent protein (EGFP), the oligonucleotides
50agctta ccat ggaccct ggggtcc gggggtc gggaaa gcgtcgcc ggtac cgg 30
and 50gatccc ggtacc ggcgac gctttc ccgac ccccg gaccc caggg tccatg
gta 30 or nucleotides of 50agctta ccatg aagc gtcgc cggta ccgg 30 and
50gatcc cggtac cggcg acg ctt 30 were annealed, phosphorylated and
cloned into the expression vector pEGFP-N1 (Clontech) at the
HindIII and BamHI sites, such that the peptide DPGVRGSGKRRRY
or KRRRY of pUL26 was fused to the N-terminus of EGFP. The
resulting construct was designated pJB730, and pJB731. The
genotypes of these plasmids were conﬁrmed by DNA sequencing
(not shown).
Capsid puriﬁcation and immunogold analyses
Monolayers of CV1 cells from two 850 cm2 roller bottles were
infected with either HSV-1(F) or mutant virus at a multiplicity of
infection (MOI) of 5 PFU per cell. At 20 h postinfection, cells were
collected into PBS and centrifuged at 4000 rpm for 5 min. Cell
pellets were suspended in lysis buffer (20 mM Tris pH 7.6,
500 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM DTT) and
protease inhibitor, sonicated, and the lysates were precleared by
centrifugation at 10,000 rpm for 15 min. The precleared lysates
were centrifuged through a 35% (wt/vol) sucrose cushion pre-
pared in TNE buffer (20 mM Tris, pH 7.6, 500 mM NaCl, and 1 mM
EDTA) at 24,000 rpm in an SW28 rotor for 60 min. The capsid
pellets were resuspended in TNE buffer and centrifuged through
20–50% sucrose gradients in an SW41 rotor at 24,500 rpm for
60 min. Capsids were visualized as light-scattering bands near the
middle of the gradient and collected with a Pasteur pipette.
Denatured capsid proteins were subjected to immunoblot analy-
sis as described previously (Yang and Baines, 2008).
Capsids were diluted into TNE buffer (Tris-HCl pH 7.8, 150 mM
NaCl, and 1 mM EDTA). Formvar/carbon-coated electron micro-
scope grids were ﬂoated on top of 10 ul drops of the diluted
capsids for 10 s at room temperature. Unbound capsids were
removed by ﬂoating the grids on 100 ul drops of TNE for 1 min at
room temperature. Previously described rabbit antiserum direc-
ted against the C terminus of pUL6 was prepared by adsorption
against capsids puriﬁed from Vero cells infected with 5.0 PFU/ml
of the UL6 viral null mutant (Yang et al., 2007). The adsorbed
antisera were then diluted 1:50 in PBS supplemented with 1%
Triton X-100 and 1% ﬁsh gelatin (PBST), and applied directly to
the electron microscopy grids for 3 h at room temperature. After
reaction with this primary Ab, the grids were washed by ﬂotation
on sequential drops of washing solutions (100 ml) for at least
1 min and then moved to fresh drops for subsequent washes. The
washes included 3 sequential ﬂotations in Phosphate buffered
(pH 7.4) 750 mM NaCl, then 5 times in PBST. Bound immunoglo-
bulins remaining after the washing were recognized by goat anti-
rabbit immunoglobulin conjugated to 12-nm gold beads. The
grids were then subjected to 5 sequential ﬂotations on 100 ml
drops of PBST, followed by 10 ﬂotations on 100 ml drops of water,
after which they were air dried. The capsids were counterstained
with 2% aqueous uranyl acetate and 0.5% Reynold’s lead citrate.
Capsids were scored as positively immunolabeled only when a
gold bead was observed in direct association with the capsid shell
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was done on a Philips 301 transmission instrument operated at
80 keV. The capsids labeled with gold beads were counted
visually and the data represent the percentage of labeled capsids
to total capsids counted. Virtually no single capsid was labeled
with more than one bead. A total of 900 capsids were counted for
each virus from a pool of three different capsid preparations, and
statistical analyses (Fisher’s exact test) were done using GraphPad
software.
Coimmunoprecipitation
Monolayers of CV1 cells from 10-cm dishes were infected with
virus as indicated in Fig. 4. At 18 h postinfection, cells were
collected in cold phosphate-buffered saline (PBS), and pelleted at
4000 rpm at 4 1C for 5 min. The cell pellets were lysed in 800 ul of
cold lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCL, 1% NP-40,
0.25% sodium deoxycholate, 1 mM EDTA and protease inhibitor)
for 30 min on ice, and the lysates were clariﬁed by centrifugation
for 10 min at 13,000 rpm in an Eppendorf microfuge. The pre-
cleared lysates (approximately 0.4 ml) were reacted with anti-
VP22a/VP21 monoclonal antibodies (MCA 406, 1:200 dilution),
and immune complexes were captured by adding 50 ml of a 50%
slurry of Gammabind G protein Sepharose beads in PBS followed
by mixing on a rotator overnight at 4 1C. The beads were pelleted
by brief centrifugation in an microfuge at 13,000 rpm at 4 1C, and
washed with excess lysis buffer four times. Each wash was
followed by brief centrifugation in a microfuge at 13,000 rpm at
4 1C. Bound proteins were eluted by resuspension of the beads in
approximately 20 ml of SDS sample buffer (4% SDS, Tris-HCl [pH
8.0], 0.01% bromophenol blue, 5 mM b-mercaptoethanol), fol-
lowed by boiling in a water bath. Liquid overlying the beads in
each sample was decanted and electrophoretically separated on a
single lane of a 10% SDS-polyacrylamide gel.
Immunoblotting
Immunoblotting was done as described previously (Yang et al.,
2007). The antibodies were diluted to 1:1000 (anti-pUL6), 1:2000
(MCA406), or 1:1000 (VP5). Detection of immune complexes on
nitrocellulose membranes was done with enhanced chemilumi-
nescence using the ECL kit from Amersham as noted previously
(Yang et al., 2009).
Immunoﬂuorescence microscopy
These procedures were performed as described previously
(Yang et al., 2007). Brieﬂy, transfected or infected CV1 cells were
ﬁxed for 10 min with 3% (wt/vol) paraformaldehyde in PBS,
permeabilized with 0.2% Triton X-100 for 5 min, and blocked
with 10% human serum for 30 min at room temperature. The cells
were then reacted with preabsorbed anti-pUL6 serum (1:100) and
anti-VP22a/VP21 (1:250) or anti-VP5 (1:100). Bound primary
antibodies were detected with goat anti-mouse IgG conjugated
to Alexa Fluor 568 (red) or goat anti-rabbit IgG conjugated to
Alexa Fluor 488 (green). The cells were viewed under a Zeiss Axio
Imager M1 ﬂuorescence microscope, using a 63 oil immersion
objective lens and the images were taken with an Axio CAM MRm
camera (Zeiss).
Virus replication assay
The procedure for assessing virus replication in various cell
lines has been described previously (Yang et al., 2007). Brieﬂy,
cells in 6-well plates were infected with the indicated viruses
(Table 1) at 0.1 PFU per cell. After 1 h incubation at 37 1C, theinocula were aspirated, and the residual extracellular infectivity
was neutralized with acid buffer (40 mM citric acid, 10 mM KCl,
and 135 mM NaCl, pH 3.0). After removal of the acid wash the
cells were overlayed with 2 ml of DMEM supplemented with 5%
newborn calf serum. Twenty hours post-infection, viruses were
released by three cycles of freezing and thawing, and the amount
of infectivity was measured in indicator cell lines CV1 (for
HSV-1(F)) or CV26-containing cell lines (for UL26 mutant viruses)
by plaque assay. The replication assays were repeated three
times, and the data were expressed as the mean7standard
deviation from three independent experiments.
Conventional electron microscopy
Cells were ﬁxed with 2.5% glutaraldehyde (Electron Microscopy
Sciences) in 0.1 M sodium cacodylate buffer, pH 7.4, for 30 min at
room temperature and then 90 min at 4 1C. After three rinses for
5 min each with the same buffer, cells were treated with 4%
osmium tetroxide for 1 h at room temperature, rinsed again with
0.1 M sodium cacodylate buffer then dehydrated with a graduated
series of ethanol concentrations (10%, 30%, 50%, 70%, and 100%)
followed by increasing concentrations of acetone (50% then two
incubations with 100%). This was followed by stepwise inﬁltration
with Epon-Araldite resin (Electron Microscopy Sciences) over the
course of 48 h at room temperature. Samples were dispensed into
beem capsules, and the resin was polymerized at 65 1C for 18 h.
Thin sections (60–90 nm thick) were collected on 300-mesh copper
grids (Ted Pella, Inc., Redding, CA). Thin sections were counter-
stained with 2% aqueous uranyl acetate for 20 min and then with
Reynolds lead citrate for 7 min. Stained grids were viewed in a
Philips 301 transmission electron microscope. All images were
collected digitally.Acknowledgments
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